Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Profession Business and Innovation, Health Economics and Policy, Cornea / Ocular Surface

Sustained Innovation

sponsored by Dompé

What is your model for drug discovery and R&D?

As an international biotech company, Dompé focuses its research and development strategy on sustainable growth, with our greatest attention devoted to patients. Our ophthalmic research discoveries are rooted in innovation with the aim of meeting the highest unmet needs of patients. We target development of new therapies and pull-through to commercialization through rigorous science with ambitious goals, seeking therapeutic answers to the unmet medical needs in ophthalmics. By combining new biotechnological knowledge with our proprietary Exscalate intelligent platform leveraging supercomputing and AI to streamline drug discovery, Dompé is accelerating the pace towards new and effective treatments.

How does Dompe ensure continued innovation in your drug discovery pipeline?

Dompé exemplifies a sustainable model with research and medical affairs activities conducted as part of a network of institutions and universities worldwide. High levels of diversity characterize our preclinical pipeline, and our research and development pipeline targets some of the hardest to treat diseases. We focus on medical conditions that are often untreated or have unmet therapeutic needs, such as neurotrophic keratitis, type 1 diabetes, and acute respiratory distress syndrome.

We have several ongoing clinical trials, and continue to build on this growth by investing a significant por tion of our revenue into research and development to continue the sustainability needed to produce data for scientific advancement.

How is your approach advancing therapeutic options in eyecare?

Dompé’s commitment to eye care is entrenched in collaboration with ophthalmologists, optometrists, patient societies, hospitals, universities, and research centers across the world.

Our researchers produced the first topical biologic treatment for neurotrophic keratitis. Additionally, Dompé specifically created the only GMP facility producing a topical growth factor for ophthalmic use. Cenegermin- bkbj (rhNGF) received “Fast-Track”, “Orphan Drug” and “Breakthrough Therapy” designations from the FDA, conferring upon it the “Priority Review” granted during the registration process. With one-market authorization utilizing rhNGF for neurotrophic keratitis, Dompé will use the neurotrophins platform to sustain the development of new applications. Our exper tise of the science behind neurotrophins is driving the evolution of our programs to evaluate potential applications of rhNGF to various ocular and systemic conditions, with the goal of fur ther advancing potential treatments in eye care and beyond. Just recently, Dompé has started two ongoing parallel investigational studies in Sjögren’s Dry Eye Disease. Recent literature continues to evolve that there is a key neurosensory component to the ocular surface manifestations in Sjögren’s Dry Eye, with alterations in corneal nerve structures and function associated with reduced tear function, inflammation, and epithelial damage. A therapeutic agent targeting the etiology of neurosensory abnormalities could be beneficial, as improved nerve health and tear production may restore ocular homeostasis.

rhNGF is under investigation in patients with Sjogren’s Dry Eye Disease, rhNGF is only FDA approved for neurotrophic keratitis.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  2. OXERVATE® (cenegermin-bkbj) ophthalmic solution 0.002% (20mcg/mL)[US package insert]. Boston, MA; Dompé U.S. Inc.; 2019.
  3. K Tsubota et al., Int J Mol Sci, 21, 9271 (2020).
Related Product Profile
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine